Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury

Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropharmacology 2024-12, Vol.261, p.110165
Hauptverfasser: Pondelick, Abby M, Moncayo, Lauren V, Donvito, Giulia, McLane, Virginia D, Gillespie, James C, Hauser, Kurt F, Spiegel, Sarah, Lichtman, Aron H, Sim-Selley, Laura J, Selley, Dana E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 110165
container_title Neuropharmacology
container_volume 261
creator Pondelick, Abby M
Moncayo, Lauren V
Donvito, Giulia
McLane, Virginia D
Gillespie, James C
Hauser, Kurt F
Spiegel, Sarah
Lichtman, Aron H
Sim-Selley, Laura J
Selley, Dana E
description Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice. Daily injections of FTY720 for 14 days dose-dependently reversed CCI-induced mechanical allodynia without tolerance development, and concomitantly resulted in a dose-dependent reduction of G-protein activation by the S1PR1-selective agonist SEW2871 in the lumbar spinal cord and brain. These findings indicate FTY720-induced desensitization of S1PR1 signaling coincides with its anti-allodynic effects. Consistent with this finding, a single injection of FTY720 reversed mechanical allodynia while concomitantly producing partial desensitization of S1PR1-stimulated G-protein activation in the CNS. However, mechanical allodynia returned 24-hr post injection, despite S1PR1 desensitization at that time, demonstrating a dissociation between these measures. Furthermore, CCI surgery led to elevations of sphingolipid metabolites, including S1P, which were unaffected by daily FTY720 administration, suggesting FTY720 reversed mechanical allodynia by targeting S1PR1 rather than sphingolipid metabolism. Supporting this hypothesis, acute administration of the S1PR1-selective agonist CYM-5442 mimicked the anti-allodynic effect of FTY720. In contrast, the S1PR1-selective antagonist NIBR-0213 prevented the anti-allodynic effect of FTY720, but NIBR-0213 given alone did not affect nociception. These results indicate that FTY720 alleviates CCI-induced allodynia through a mechanism distinct from functional antagonism.
doi_str_mv 10.1016/j.neuropharm.2024.110165
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_39303855</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>39303855</sourcerecordid><originalsourceid>FETCH-pubmed_primary_393038553</originalsourceid><addsrcrecordid>eNqFj81OwzAQhC0kRMvPK6A9wiHBzk8TzkDLEYleOFWuvaEbJXZkO0XhtXhBXApnLrua1aeZWcZA8FRwsbhrU4Ojs8NOuj7NeFak4nAvT9hc1FWeVHxRzNi59y3nvKhFfcZm-X3O87os5-zrkby3imQga2CL4QPRQNghSBMokV1n9WRIATYNquDBNtCQebcd9VbDzXL9VmX8NtIaNHo0ngJ9Ht0i-ipeQIBDhUOwLulRxyTUsEoGZwOSAakC7Y_8QUFvR49xauwOBv6nmgKDbo-RaEc3XbLTRnYer373BbtePq0fnpNh3MaEzeCol27a_H2Z_wt8AyE0aNY</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Pondelick, Abby M ; Moncayo, Lauren V ; Donvito, Giulia ; McLane, Virginia D ; Gillespie, James C ; Hauser, Kurt F ; Spiegel, Sarah ; Lichtman, Aron H ; Sim-Selley, Laura J ; Selley, Dana E</creator><creatorcontrib>Pondelick, Abby M ; Moncayo, Lauren V ; Donvito, Giulia ; McLane, Virginia D ; Gillespie, James C ; Hauser, Kurt F ; Spiegel, Sarah ; Lichtman, Aron H ; Sim-Selley, Laura J ; Selley, Dana E</creatorcontrib><description>Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice. Daily injections of FTY720 for 14 days dose-dependently reversed CCI-induced mechanical allodynia without tolerance development, and concomitantly resulted in a dose-dependent reduction of G-protein activation by the S1PR1-selective agonist SEW2871 in the lumbar spinal cord and brain. These findings indicate FTY720-induced desensitization of S1PR1 signaling coincides with its anti-allodynic effects. Consistent with this finding, a single injection of FTY720 reversed mechanical allodynia while concomitantly producing partial desensitization of S1PR1-stimulated G-protein activation in the CNS. However, mechanical allodynia returned 24-hr post injection, despite S1PR1 desensitization at that time, demonstrating a dissociation between these measures. Furthermore, CCI surgery led to elevations of sphingolipid metabolites, including S1P, which were unaffected by daily FTY720 administration, suggesting FTY720 reversed mechanical allodynia by targeting S1PR1 rather than sphingolipid metabolism. Supporting this hypothesis, acute administration of the S1PR1-selective agonist CYM-5442 mimicked the anti-allodynic effect of FTY720. In contrast, the S1PR1-selective antagonist NIBR-0213 prevented the anti-allodynic effect of FTY720, but NIBR-0213 given alone did not affect nociception. These results indicate that FTY720 alleviates CCI-induced allodynia through a mechanism distinct from functional antagonism.</description><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2024.110165</identifier><identifier>PMID: 39303855</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Female ; Fingolimod Hydrochloride - pharmacology ; Hyperalgesia - drug therapy ; Hyperalgesia - metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Neuralgia - drug therapy ; Neuralgia - metabolism ; Oxadiazoles - pharmacology ; Receptors, Lysosphingolipid - agonists ; Receptors, Lysosphingolipid - metabolism ; Sciatic Nerve - drug effects ; Sciatic Nerve - injuries ; Sciatic Neuropathy - drug therapy ; Sciatic Neuropathy - metabolism ; Sphingosine - analogs &amp; derivatives ; Sphingosine - pharmacology ; Sphingosine 1 Phosphate Receptor Modulators - pharmacology ; Sphingosine-1-Phosphate Receptors - agonists ; Sphingosine-1-Phosphate Receptors - metabolism</subject><ispartof>Neuropharmacology, 2024-12, Vol.261, p.110165</ispartof><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39303855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pondelick, Abby M</creatorcontrib><creatorcontrib>Moncayo, Lauren V</creatorcontrib><creatorcontrib>Donvito, Giulia</creatorcontrib><creatorcontrib>McLane, Virginia D</creatorcontrib><creatorcontrib>Gillespie, James C</creatorcontrib><creatorcontrib>Hauser, Kurt F</creatorcontrib><creatorcontrib>Spiegel, Sarah</creatorcontrib><creatorcontrib>Lichtman, Aron H</creatorcontrib><creatorcontrib>Sim-Selley, Laura J</creatorcontrib><creatorcontrib>Selley, Dana E</creatorcontrib><title>Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice. Daily injections of FTY720 for 14 days dose-dependently reversed CCI-induced mechanical allodynia without tolerance development, and concomitantly resulted in a dose-dependent reduction of G-protein activation by the S1PR1-selective agonist SEW2871 in the lumbar spinal cord and brain. These findings indicate FTY720-induced desensitization of S1PR1 signaling coincides with its anti-allodynic effects. Consistent with this finding, a single injection of FTY720 reversed mechanical allodynia while concomitantly producing partial desensitization of S1PR1-stimulated G-protein activation in the CNS. However, mechanical allodynia returned 24-hr post injection, despite S1PR1 desensitization at that time, demonstrating a dissociation between these measures. Furthermore, CCI surgery led to elevations of sphingolipid metabolites, including S1P, which were unaffected by daily FTY720 administration, suggesting FTY720 reversed mechanical allodynia by targeting S1PR1 rather than sphingolipid metabolism. Supporting this hypothesis, acute administration of the S1PR1-selective agonist CYM-5442 mimicked the anti-allodynic effect of FTY720. In contrast, the S1PR1-selective antagonist NIBR-0213 prevented the anti-allodynic effect of FTY720, but NIBR-0213 given alone did not affect nociception. These results indicate that FTY720 alleviates CCI-induced allodynia through a mechanism distinct from functional antagonism.</description><subject>Animals</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Fingolimod Hydrochloride - pharmacology</subject><subject>Hyperalgesia - drug therapy</subject><subject>Hyperalgesia - metabolism</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Neuralgia - drug therapy</subject><subject>Neuralgia - metabolism</subject><subject>Oxadiazoles - pharmacology</subject><subject>Receptors, Lysosphingolipid - agonists</subject><subject>Receptors, Lysosphingolipid - metabolism</subject><subject>Sciatic Nerve - drug effects</subject><subject>Sciatic Nerve - injuries</subject><subject>Sciatic Neuropathy - drug therapy</subject><subject>Sciatic Neuropathy - metabolism</subject><subject>Sphingosine - analogs &amp; derivatives</subject><subject>Sphingosine - pharmacology</subject><subject>Sphingosine 1 Phosphate Receptor Modulators - pharmacology</subject><subject>Sphingosine-1-Phosphate Receptors - agonists</subject><subject>Sphingosine-1-Phosphate Receptors - metabolism</subject><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFj81OwzAQhC0kRMvPK6A9wiHBzk8TzkDLEYleOFWuvaEbJXZkO0XhtXhBXApnLrua1aeZWcZA8FRwsbhrU4Ojs8NOuj7NeFak4nAvT9hc1FWeVHxRzNi59y3nvKhFfcZm-X3O87os5-zrkby3imQga2CL4QPRQNghSBMokV1n9WRIATYNquDBNtCQebcd9VbDzXL9VmX8NtIaNHo0ngJ9Ht0i-ipeQIBDhUOwLulRxyTUsEoGZwOSAakC7Y_8QUFvR49xauwOBv6nmgKDbo-RaEc3XbLTRnYer373BbtePq0fnpNh3MaEzeCol27a_H2Z_wt8AyE0aNY</recordid><startdate>20241215</startdate><enddate>20241215</enddate><creator>Pondelick, Abby M</creator><creator>Moncayo, Lauren V</creator><creator>Donvito, Giulia</creator><creator>McLane, Virginia D</creator><creator>Gillespie, James C</creator><creator>Hauser, Kurt F</creator><creator>Spiegel, Sarah</creator><creator>Lichtman, Aron H</creator><creator>Sim-Selley, Laura J</creator><creator>Selley, Dana E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20241215</creationdate><title>Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury</title><author>Pondelick, Abby M ; Moncayo, Lauren V ; Donvito, Giulia ; McLane, Virginia D ; Gillespie, James C ; Hauser, Kurt F ; Spiegel, Sarah ; Lichtman, Aron H ; Sim-Selley, Laura J ; Selley, Dana E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_393038553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Fingolimod Hydrochloride - pharmacology</topic><topic>Hyperalgesia - drug therapy</topic><topic>Hyperalgesia - metabolism</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Neuralgia - drug therapy</topic><topic>Neuralgia - metabolism</topic><topic>Oxadiazoles - pharmacology</topic><topic>Receptors, Lysosphingolipid - agonists</topic><topic>Receptors, Lysosphingolipid - metabolism</topic><topic>Sciatic Nerve - drug effects</topic><topic>Sciatic Nerve - injuries</topic><topic>Sciatic Neuropathy - drug therapy</topic><topic>Sciatic Neuropathy - metabolism</topic><topic>Sphingosine - analogs &amp; derivatives</topic><topic>Sphingosine - pharmacology</topic><topic>Sphingosine 1 Phosphate Receptor Modulators - pharmacology</topic><topic>Sphingosine-1-Phosphate Receptors - agonists</topic><topic>Sphingosine-1-Phosphate Receptors - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pondelick, Abby M</creatorcontrib><creatorcontrib>Moncayo, Lauren V</creatorcontrib><creatorcontrib>Donvito, Giulia</creatorcontrib><creatorcontrib>McLane, Virginia D</creatorcontrib><creatorcontrib>Gillespie, James C</creatorcontrib><creatorcontrib>Hauser, Kurt F</creatorcontrib><creatorcontrib>Spiegel, Sarah</creatorcontrib><creatorcontrib>Lichtman, Aron H</creatorcontrib><creatorcontrib>Sim-Selley, Laura J</creatorcontrib><creatorcontrib>Selley, Dana E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pondelick, Abby M</au><au>Moncayo, Lauren V</au><au>Donvito, Giulia</au><au>McLane, Virginia D</au><au>Gillespie, James C</au><au>Hauser, Kurt F</au><au>Spiegel, Sarah</au><au>Lichtman, Aron H</au><au>Sim-Selley, Laura J</au><au>Selley, Dana E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2024-12-15</date><risdate>2024</risdate><volume>261</volume><spage>110165</spage><pages>110165-</pages><eissn>1873-7064</eissn><abstract>Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice. Daily injections of FTY720 for 14 days dose-dependently reversed CCI-induced mechanical allodynia without tolerance development, and concomitantly resulted in a dose-dependent reduction of G-protein activation by the S1PR1-selective agonist SEW2871 in the lumbar spinal cord and brain. These findings indicate FTY720-induced desensitization of S1PR1 signaling coincides with its anti-allodynic effects. Consistent with this finding, a single injection of FTY720 reversed mechanical allodynia while concomitantly producing partial desensitization of S1PR1-stimulated G-protein activation in the CNS. However, mechanical allodynia returned 24-hr post injection, despite S1PR1 desensitization at that time, demonstrating a dissociation between these measures. Furthermore, CCI surgery led to elevations of sphingolipid metabolites, including S1P, which were unaffected by daily FTY720 administration, suggesting FTY720 reversed mechanical allodynia by targeting S1PR1 rather than sphingolipid metabolism. Supporting this hypothesis, acute administration of the S1PR1-selective agonist CYM-5442 mimicked the anti-allodynic effect of FTY720. In contrast, the S1PR1-selective antagonist NIBR-0213 prevented the anti-allodynic effect of FTY720, but NIBR-0213 given alone did not affect nociception. These results indicate that FTY720 alleviates CCI-induced allodynia through a mechanism distinct from functional antagonism.</abstract><cop>England</cop><pmid>39303855</pmid><doi>10.1016/j.neuropharm.2024.110165</doi></addata></record>
fulltext fulltext
identifier EISSN: 1873-7064
ispartof Neuropharmacology, 2024-12, Vol.261, p.110165
issn 1873-7064
language eng
recordid cdi_pubmed_primary_39303855
source MEDLINE; Elsevier ScienceDirect Journals
subjects Animals
Disease Models, Animal
Dose-Response Relationship, Drug
Female
Fingolimod Hydrochloride - pharmacology
Hyperalgesia - drug therapy
Hyperalgesia - metabolism
Male
Mice
Mice, Inbred C57BL
Neuralgia - drug therapy
Neuralgia - metabolism
Oxadiazoles - pharmacology
Receptors, Lysosphingolipid - agonists
Receptors, Lysosphingolipid - metabolism
Sciatic Nerve - drug effects
Sciatic Nerve - injuries
Sciatic Neuropathy - drug therapy
Sciatic Neuropathy - metabolism
Sphingosine - analogs & derivatives
Sphingosine - pharmacology
Sphingosine 1 Phosphate Receptor Modulators - pharmacology
Sphingosine-1-Phosphate Receptors - agonists
Sphingosine-1-Phosphate Receptors - metabolism
title Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P 1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T07%3A16%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dissociation%20between%20the%20anti-allodynic%20effects%20of%20fingolimod%20(FTY720)%20and%20desensitization%20of%20S1P%201%20receptor-mediated%20G-protein%20activation%20in%20a%20mouse%20model%20of%20sciatic%20nerve%20injury&rft.jtitle=Neuropharmacology&rft.au=Pondelick,%20Abby%20M&rft.date=2024-12-15&rft.volume=261&rft.spage=110165&rft.pages=110165-&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2024.110165&rft_dat=%3Cpubmed%3E39303855%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/39303855&rfr_iscdi=true